Showing 2921-2930 of 4166 results for "".
- Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Diseasehttps://modernod.com/news/optos-and-amydis-establish-clinical-alliance-to-develop-early-diagnostic-test-for-alzheimers-disease/2479754/Optos, a subsidiary of Nikon Corporation, and Amydis announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ optomap ultra-wi
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAOhttps://modernod.com/news/aura-biosciences-to-present-phase-1b-2-clinical-data-for-au-011-at-aao/2479786/Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27
- Ophthotech Completes Patient Recruitment for Its Phase 2b Clinical Trial of Zimura for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/ophthotech-completes-patient-recruitment-for-its-phase-2b-clinical-trial-of-zimura-for-geographic-atrophy-secondary-to-dry-amd/2479816/Ophthotech announced completion of patient recruitment for its phase 2b clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). Complement factor C5
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the
- REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trialshttps://modernod.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/REGENXBIO Inc. announced financial results for the quarter ended June 30, 2018, and recent operational highlights including updates to interim data from its ongoing clinical trials. Financial Results Cash, cash equivalents, and marketable securities were $306.3 million as of June
- Allergan and Molecular Partners Announce Positive Phase 3 Clinical Trials for Abicipar Pegol for the Treatment of Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-positive-phase-3-clinical-trials-for-abicipar-pegol-for-the-treatment-of-wet-amd/2480008/Allergan and Molecular Partners announced the release of two positive clinical trials, SEQUOIA and CEDAR, for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the prespecified primary endpoint of noninferiority to ranibizumab. SEQUOIA and CEDAR are identical
- Oyster Point Announces Positive Results from Phase 2 Clinical Trial of Investigational Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/Oyster Point Pharma announced results from the PEARL study, a phase 2b clinical trial evaluating the company’s novel therapy for the treatment of dry eye disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a v
- Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Diseasehttps://modernod.com/news/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-host-disease/2480053/Ocugen announced that it has initiated the first of two pivotal, phase 3 clinical trials of OCU300 for the treatment of ocular discomfort and ocular redness in patients with ocular graft versus host disease (oGVHD) following recent acceptance of Ocugen’s investigational new drug (IND) appli
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a